Hiraoka Arudo, Nakajima Kosuke, Kuinose Masahiko, Totsugawa Toshinori, Yoshitaka Hidenori
Department of Cardiovascular Surgery, The Sakakibara Heart Institute of Okayama, Okayama, Japan.
Asian Cardiovasc Thorac Ann. 2014 Mar;22(3):267-71. doi: 10.1177/0218492313480357. Epub 2013 Sep 4.
We introduced an initial large dose of modified St. Thomas' Hospital cardioplegic solution with the aim of providing both myocardial protection as well as a smooth intraoperative process.
In 90 cases of isolated aortic valve replacement, we used the modified technique of cardioplegia in 45 (group S) and conventional administration of glucose-insulin-potassium solution in 45 (group G). The patients were selected at random. In group S, we added 4 mEq of potassium to the original St. Thomas' Hospital solution and administered 30 mL·kg(-1) as an initial dose. The temperature was decreased to 2.
The mean of reperfusion time after declamping in group S was significantly shorter (16.7 ± 6.4 vs. 21.5 ± 10.0 min; p = 0.007). The average of postoperative maximum creatine kinase-MB was significantly lower in group S (25.6 ± 9.5 vs. 40.6 ± 37.2 IU·L(-1); p = 0.014). On multivariate analysis, use of the modified cardioplegia and aortic crossclamp time were significantly associated with creatine kinase-MB level and reperfusion time after declamping.
This modified technique was an acceptable option that provided a bloodless operative field and avoided multiple cardioplegic administrations.
我们引入了初始大剂量的改良圣托马斯医院心脏停搏液,目的是提供心肌保护以及术中平稳过程。
在90例单纯主动脉瓣置换术中,45例采用改良心脏停搏技术(S组),45例采用常规葡萄糖 - 胰岛素 - 钾溶液给药(G组)。患者随机选择。在S组中,我们在原圣托马斯医院溶液中添加4 mEq钾,并以30 mL·kg(-1)作为初始剂量给药。温度降至2℃。
S组松开阻断钳后的再灌注时间平均值显著缩短(16.7±6.4对21.5±10.0分钟;p = 0.007)。S组术后最大肌酸激酶 - MB平均值显著更低(25.6±9.5对40.6±37.2 IU·L(-1);p = 0.014)。多因素分析显示,改良心脏停搏技术的使用和主动脉阻断时间与肌酸激酶 - MB水平及松开阻断钳后的再灌注时间显著相关。
这种改良技术是一种可接受的选择,可提供无血手术视野并避免多次心脏停搏液给药。